New Inhaled Antibiotic

[Guest guest]

PR Newswire

                                                       

May 28, 2003, Wednesday

HEADLINE: IND Filed for Corus 1020 and First Cystic Fibrosis Patient

Enrolled in Phase Ib Study

DATELINE: SEATTLE, May 28

Corus Pharma announced that its wholly owned subsidiary Salus Pharma has

filed its IND (Investigational New Drug) application with the Food &

Drug Administration for Corus 1020 (aztreonam formulated for inhalation)

and dosed its first cystic fibrosis patient in a Phase Ib study.

The U.S. multi-center, randomized, blinded study is evaluating the

safety and tolerability of Corus 1020 in patients with cystic fibrosis.

Corus 1020 is an inhaled antibiotic that has a broad spectrum of

activity against gram-negative bacteria. The product will be delivered

directly to the lung to increase the concentration of the drug at the

site of infection. Salus utilized Pari GmbH's formulation services for

the placebo and aztreonam formulated for inhalation, and will utilize

Pari's eFlow inhalation technology to administer the placebo and

drug.

" This is an exciting step forward, " said A. Bruce Montgomery, CEO of

Corus Pharma. " Corus 1020 was well-tolerated in our first study and we

hope to have similar results in CF patients. We expect to move into a

Phase II study later this year. "

About Cystic Fibrosis

Cystic Fibrosis (CF) is a chronic, debilitating genetic disease that

affects about 30,000 Americans. A major characteristic of CF is

production of abnormally thick, sticky mucus in the lungs, trapping

bacteria and predisposing patients to lung infections, which continually

damage their lungs. In the United States, 50 percent of all CF patients

die by age 24, with bacterial-caused lung damage accounting, directly or

indirectly, for more than 90 percent of all CF patient deaths.

About Corus Pharma

Corus Pharma, a Seattle-based pharmaceutical development company, is

committed to developing and obtaining regulatory approvals of products

for respiratory and infectious diseases that can help provide improved

health and superior quality of life. More information about Corus Pharma

may be found at www.coruspharma.com.

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/